Abstract:Cancer is a complex genetic and epigenetic-based disease that has developed an armada of mechanisms to escape cell death. The deregulation of apoptosis and autophagy, which are basic processes essential for normal cellular activity, are commonly encountered during the development of human tumors. In order to assist the cancer cell in defeating the imbalance between cell growth and cell death, histone deacetylase inhibitors (HDACi) have been employed to reverse epigenetically deregulated gene expression caused by aberrant post-translational protein modifications. These interfere with histone acetyltransferase- and deacetylase-mediated acetylation of both histone and non-histone proteins, and thereby exert a wide array of HDACi-stimulated cytotoxic effects. Key determinants of HDACi lethality that interfere with cellular growth in a multitude of tumor cells are apoptosis and autophagy, which are either mutually exclusive or activated in combination. Here, we compile known molecular signals and pathways involved in the HDACi-triggered induction of apoptosis and autophagy. Currently, the factors that determine the mode of HDACi-elicited cell death are mostly unclear. Correspondingly, we also summarized as yet established intertwined mechanisms, in particular with respect to the oncogenic tumor suppressor protein p53, that drive the interplay between apoptosis and autophagy in response to HDACi. In this context, we also note the significance to determine the presence of functional p53 protein levels in the cancer cell. The confirmation of the context-dependent function of autophagy will pave the way to improve the benefit from HDACi-mediated cancer treatment.

Histone Deacetylase Inhibitors and Cell Death.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Cyclic Peptide Histone Deacetylase Inhibitors

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Anticancer activities of histone deacetylase inhibitors

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Histone Deacetylase Inhibitors as Anticancer Drugs

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

The emerging roles of HDACs and their therapeutic implications in cancer

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

New Development of HDAC Inhibitors As Anti-Cancer Agents

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

Targeting histone deacetylase in cardiac diseases

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.